公开(公告)号：US20050201950A1

公开(公告)日：2005-09-15

申请号：US11073625

申请日：2005-03-08

申请人： John Staniforth ,  David Vodden Morton ,  Rajbir Gill ,  Gaetano Brambilla ,  Rossella Musa ,  Lorenzo Ferrarini

发明人： John Staniforth ,  David Vodden Morton ,  Rajbir Gill ,  Gaetano Brambilla ,  Rossella Musa ,  Lorenzo Ferrarini

IPC分类号： A61K9/72 ,  A61K9/00 ,  A61K9/12 ,  A61K9/14 ,  A61K9/16 ,  A61K31/135 ,  A61K31/167 ,  A61K31/47 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7012 ,  A61K38/28 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/44 ,  A61L9/04 ,  A61P11/00 ,  A61P11/06

CPC分类号： A61K9/0075 ,  A61K9/0078 ,  A61K9/145 ,  A61K31/167 ,  A61K31/573 ,  A61K31/58

摘要： The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering of pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation freely flowable, which can be produced in a simple way, physically and chemically stable and able of delivering either accurate doses and high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.